This site is intended for health professionals only
Newsletter
Hospital Healthcare Europe
Login
Twitter
Linkedin
Facebook
Select Language
English
French
German
Italian
Spanish
News
Views
Reviews & Research
Clinical
Cardiovascular
Dermatology
Gastroenterology
Medicines safety
Mental health
Neurology
Oncology
Paediatrics
Respiratory
Rheumatology
Sponsored
Events
News
Views
Reviews & Research
Clinical
Cardiovascular
Dermatology
Gastroenterology
Medicines safety
Mental health
Neurology
Oncology
Paediatrics
Respiratory
Rheumatology
Sponsored
Events
Home
>
Mental health
Mental health
Molecular trigger for Alzheimer’s disease
Vortioxetine clinical phase III data in depression
Lundbeck announces positive results for Brintellix™
Orion Phase II data Alzheimer’s disease drug
Otsuka and Lundbeck expand their existing collaboration
FDA accepts Takeda and Lundbeck’s filing for review of Brintellix
Vortioxetine filed in the US and EU
Takeda and Lundbeck announce the submission for vortioxetine
World Alzheimer’s Day: EAHP president highlights the need for dementia-friendly health systems
Lundbeck files for regulatory approval of vortioxetine
Asenapine in bipolar mania
Lundbeck financial expectation on track
« Previous
1
…
7
8
9
10
11
…
26
Next »
Most read
1
Oral vitamin A could become an alternative to isotretinoin for acne
by Rod Tucker
2
Transcranial magnetic stimulation brain connectivity changes in major depression visible on MRI scan
by Rod Tucker
3
Amino acids supplement reduces muscle wasting and improves gut function in critically ill
by Rod Tucker
4
Less than two-thirds of patients alive 10 years after out-of-hospital cardiac arrest
by Rod Tucker
5
Launch of the new Hospital Pharmacy Europe Mobile App
by aporter2
Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Subscribe
x
Search for: